Genetics screening in an Italian cohort of patients with Amyotrophic Lateral Sclerosis: the importance of early testing and its implication.
Amyotrophic Lateral Sclerosis
Genetic screening
Neurological disease
Variants SOD1
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
06
09
2023
accepted:
29
11
2023
revised:
28
11
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease with an elusive etiology. While environmental factors have been considered, familial ALS cases have raised the possibility of genetic involvement. This genetic connection is increasingly evident, even in patients with sporadic ALS. We allowed access to the genetic test to all patients attending our clinic to identify the prevalence and the role of genetic variants in the development of the disease and to identify patients with potentially treatable forms of the disease. 194 patients with probable or definite ALS, were enrolled. A comprehensive genetic testing was performed, including sequencing all exons of the SOD1 gene and testing for hexanucleotide intronic repeat expansions (G4C2) in the C9orf72 gene using fluorescent repeat-primed PCR (RP-PCR). Whole Exome NGS Sequencing (WES) was performed, followed by an in silico multigene panel targeting neuromuscular diseases, spastic paraplegia, and motor distal neuropathies. We conducted statistical analyses to compare different patient groups. Clinically significant pathogenetic variants were detected in 14.43% of cases. The highest prevalence of pathogenetic variants was observed in fALS patients, but a substantial proportion of sALS patients also displayed at least one variant, either pathogenetic or of uncertain significance (VUS). The most observed pathogenetic variant was the expansion of the C9orf72 gene, which was associated with a shorter survival. SOD1 variants were found in 1.6% of fALS and 2.5% of sALS patients. The study reveals a significant number of ALS patients carrying pathogenic or likely pathogenic variants, with a higher prevalence in familial ALS cases. The expansion of the C9orf72 gene emerges as the most common genetic cause of ALS, affecting familial and sporadic cases. Additionally, SOD1 variants are detected at an unexpectedly higher rate, even in patients without a familial history of ALS, underscoring the crucial role of genetic testing in treatment decisions and potential participation in clinical trials. We also investigated variants in genes such as TARDBP, FUS, NEK1, TBK1, and DNAJC7, shedding light on their potential involvement in ALS. These findings underscore the complexity of interpreting variants of uncertain significance (VUS) and their ethical implications in patient communication and genetic counseling for patients' relatives. This study emphasizes the diverse genetic basis of ALS and advocates for integrating comprehensive genetic testing into diagnostic protocols. The evolving landscape of genetic therapies requires identifying all eligible patients transcending traditional familial boundaries. The presence of VUS highlights the multifaceted nature of ALS genetics, prompting further exploration of complex interactions among genetic variants, environmental factors, and disease development.
Identifiants
pubmed: 38112783
doi: 10.1007/s00415-023-12142-x
pii: 10.1007/s00415-023-12142-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377(2):162–172
pubmed: 28700839
doi: 10.1056/NEJMra1603471
Chiò A et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41(2):118–130
pubmed: 23860588
doi: 10.1159/000351153
Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9(11):617–628
pubmed: 24126629
doi: 10.1038/nrneurol.2013.203
Kiernan MC et al (2011) Amyotrophic lateral sclerosis. Lancet (London, England) 377(9769):942–955
pubmed: 21296405
doi: 10.1016/S0140-6736(10)61156-7
Pender N, Pinto-Grau M, Hardiman O (2020) Cognitive and behavioural impairment in amyotrophic lateral sclerosis. Curr Opin Neurol 33(5):649–654
pubmed: 32833751
doi: 10.1097/WCO.0000000000000862
Wang M-D et al (2017) Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology 61:101–130
pubmed: 27377857
doi: 10.1016/j.neuro.2016.06.015
Qiu X-B et al (2006) The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci: CMLS 63(22):2560–2570
pubmed: 16952052
doi: 10.1007/s00018-006-6192-6
Kurland LT, Mulder DW (1955) Epidemiologic investigations of amyotrophic lateral sclerosis. 2. Familial aggregations indicative of dominant inheritance. I Neurol 5(3):182–196
Perrone B, Conforti FL (2020) Common mutations of interest in the diagnosis of amyotrophic lateral sclerosis: how common are common mutations in ALS genes? Expert Rev Mol Diagn 20(7):703–714
pubmed: 32497448
doi: 10.1080/14737159.2020.1779060
Chia R, Chiò A, Traynor BJ (2018) Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 17(1):94–102
pubmed: 29154141
doi: 10.1016/S1474-4422(17)30401-5
Wroe R et al (2008) ALSOD: the amyotrophic lateral sclerosis online database. Amyotroph Lateral Scler: Off Publ World Fed Neurol Res Group Motor Neuron Dis 9(4):249–250
doi: 10.1080/17482960802146106
Renton AE, Chiò A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17(1):17–23
pubmed: 24369373
doi: 10.1038/nn.3584
Cooper-Knock J, Shaw PJ, Kirby J (2014) The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol 127(3):333–345
pubmed: 24493408
pmcid: 3925297
doi: 10.1007/s00401-014-1251-9
Al-Chalabi A et al (2010) An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 81(12):1324–1326
pubmed: 20861059
doi: 10.1136/jnnp.2010.207464
Al-Chalabi A, Lewis CM (2011) Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered 71(4):281–288
pubmed: 21846995
doi: 10.1159/000330167
Al-Chalabi A, van den Berg LH, Veldink J (2017) Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol 13(2):96–104
pubmed: 27982040
doi: 10.1038/nrneurol.2016.182
Al-Chalabi A et al (2014) Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 13(11):1108–1113
pubmed: 25300936
pmcid: 4197338
doi: 10.1016/S1474-4422(14)70219-4
Vucic S et al (2020) ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology 94(15):e1657–e1663
pubmed: 32071166
pmcid: 7251515
doi: 10.1212/WNL.0000000000009015
Miller T et al (2020) Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 383(2):109–119
pubmed: 32640130
doi: 10.1056/NEJMoa2003715
Salmon K et al (2022) The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain J Neurol 145(4):1207–1210
doi: 10.1093/brain/awab472
Shepheard SR et al (2021) Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 92(5):510–518
pubmed: 33589474
doi: 10.1136/jnnp-2020-325014
Brooks BR et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord: Off Publ World Fed Neurol, Res Group Motor Neuron Dis 1(5):293–299
doi: 10.1080/146608200300079536
Byrne S et al (2011) Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 12(3):157–159
pubmed: 21208036
doi: 10.3109/17482968.2010.545420
Paulson H (2018) Repeat expansion diseases. Handb Clin Neurol 147:105–123
pubmed: 29325606
pmcid: 6485936
doi: 10.1016/B978-0-444-63233-3.00009-9
van Blitterswijk M et al (2012) Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet 21(17):3776–3784
pubmed: 22645277
doi: 10.1093/hmg/dds199
Shibuya K et al (2021) Facial onset amyotrophic lateral sclerosis with K3E variant in the Cu/Zn superoxide dismutase gene. Amyotroph Lateral Scler Frontotemporal Degener 22(1–2):144–146
pubmed: 32729725
doi: 10.1080/21678421.2020.1797092
Chen LX et al (2021) SOD1 mutation spectrum and natural history of ALS patients in a 15-year cohort in Southeastern China. Front Genet 12:746060
pubmed: 34721532
pmcid: 8551486
doi: 10.3389/fgene.2021.746060
Pang SY et al (2017) Burden of rare variants in ALS genes influences survival in familial and sporadic ALS. Neurobiol Aging 58:238.e9-238.e15
pubmed: 28709720
doi: 10.1016/j.neurobiolaging.2017.06.007
Tasca G et al (2020) SOD1 p.D12Y variant is associated with amyotrophic lateral sclerosis/distal myopathy spectrum. Eur J Neurol 27(7):1304–1309
pubmed: 32250500
doi: 10.1111/ene.14246
Weber M et al (2012) ALS patients with SOD1 mutations in Switzerland show very diverse phenotypes and extremely long survival. J Neurol Neurosurg Psychiatry 83(3):351–353
pubmed: 21700728
doi: 10.1136/jnnp.2011.241349
Chiò A et al (2010) Amyotrophic lateral sclerosis-frontotemporal lobar dementia in 3 families with p.Ala382Thr TARDBP mutations. Arch Neurol 67(8):1002–1009
pubmed: 20697052
pmcid: 3535689
doi: 10.1001/archneurol.2010.173
Quadri M et al (2011) Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson’s disease in Sardinia. Neurogenetics 12(3):203–209
pubmed: 21667065
pmcid: 3158341
doi: 10.1007/s10048-011-0288-3
Tunca C et al (2020) Revisiting the complex architecture of ALS in Turkey: expanding genotypes, shared phenotypes, molecular networks, and a public variant database. Hum Mutat 41(8):e7–e45
pubmed: 32579787
doi: 10.1002/humu.24055
Kenna KP et al (2016) NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet 48(9):1037–1042
pubmed: 27455347
pmcid: 5560030
doi: 10.1038/ng.3626
Zhang L et al (2004) GC/AT-content spikes as genomic punctuation marks. Proc Natl Acad Sci 101(48):16855–16860
pubmed: 15548610
pmcid: 534751
doi: 10.1073/pnas.0407821101
Dilliott AA et al (2022) DnaJC7 in amyotrophic lateral sclerosis. Int J Mol Sci 23(8):4076
pubmed: 35456894
pmcid: 9025444
doi: 10.3390/ijms23084076
Farhan SMK et al (2019) Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. Nat Neurosci 22(12):1966–1974
pubmed: 31768050
pmcid: 6919277
doi: 10.1038/s41593-019-0530-0
Azzedine H et al (2013) PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth disease. Hum Mol Genet 22(20):4224–4232
pubmed: 23777631
pmcid: 3983407
doi: 10.1093/hmg/ddt274
Karch CM et al (2016) Missense mutations in progranulin gene associated with frontotemporal lobar degeneration: study of pathogenetic features. Neurobiol Aging 38:215.e1-215.e12
pubmed: 26652843
doi: 10.1016/j.neurobiolaging.2015.10.029
Stevanin G et al (2007) Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet 39(3):366–372
pubmed: 17322883
doi: 10.1038/ng1980
D’Amore A et al (2018) Next generation molecular diagnosis of hereditary spastic paraplegias: an Italian cross-sectional study. Front Neurol 9:981
pubmed: 30564185
pmcid: 6289125
doi: 10.3389/fneur.2018.00981
Richards S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17(5):405–423
pubmed: 25741868
pmcid: 4544753
doi: 10.1038/gim.2015.30
Grassano M et al (2022) Systematic evaluation of genetic mutations in ALS: a population-based study. J Neurol Neurosurg Psychiatry 93(11):1190–1193
pubmed: 35896380
doi: 10.1136/jnnp-2022-328931
Mehta PR et al (2019) Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias. J Neurol Neurosurg Psychiatry 90(3):268–271
pubmed: 30270202
doi: 10.1136/jnnp-2018-319089
Beckers J, Tharkeshwar AK, Van Damme P (2021) C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy 17(11):3306–3322
pubmed: 33632058
pmcid: 8632097
doi: 10.1080/15548627.2021.1872189
Chiò A et al (2012) ALS/FTD phenotype in two Sardinian families carrying both C9ORF72 and TARDBP mutations. J Neurol Neurosurg Psychiatry 83(7):730–733
pubmed: 22550220
doi: 10.1136/jnnp-2012-302219
Kaivorinne AL et al (2014) Novel TARDBP sequence variant and C9ORF72 repeat expansion in a family with frontotemporal dementia. Alzheimer Dis Assoc Disord 28(2):190–193
pubmed: 22892647
pmcid: 3511614
doi: 10.1097/WAD.0b013e318266fae5
van Blitterswijk M et al (2013) C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology 81(15):1332–1341
pubmed: 24027057
pmcid: 3806926
doi: 10.1212/WNL.0b013e3182a8250c
King A et al (2013) Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant. Acta Neuropathol 125(2):303–310
pubmed: 23053136
doi: 10.1007/s00401-012-1050-0
Millecamps S et al (2012) Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet 49(4):258–263
pubmed: 22499346
doi: 10.1136/jmedgenet-2011-100699
Cooper-Knock J et al (2012) Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 135(Pt 3):751–764
pubmed: 22366792
pmcid: 3286332
doi: 10.1093/brain/awr365
Testi S et al (2015) Co-occurrence of the C9ORF72 expansion and a novel GRN mutation in a family with alternative expression of frontotemporal dementia and amyotrophic lateral sclerosis. J Alzheimers Dis 44(1):49–56
pubmed: 25182743
doi: 10.3233/JAD-141794
Umoh ME et al (2016) Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology 87(10):1024–1030
pubmed: 27488601
pmcid: 5027809
doi: 10.1212/WNL.0000000000003067
Bernard E et al (2020) Clinical and molecular landscape of ALS patients with SOD1 mutations: novel pathogenic variants and novel phenotypes. A single ALS center study. Int J Mol Sci 21(18):6807
pubmed: 32948071
pmcid: 7554847
doi: 10.3390/ijms21186807
Olsen CG et al (2022) Genetic epidemiology of amyotrophic lateral sclerosis in Norway: a 2-year population-based study. Neuroepidemiology 56(4):271–282
pubmed: 35576897
doi: 10.1159/000525091
Gagliardi D et al (2023) Clinical and molecular features of patients with amyotrophic lateral sclerosis and. Front Neurol 14:1169689
pubmed: 37265463
pmcid: 10230028
doi: 10.3389/fneur.2023.1169689
Opie-Martin S et al (2022) The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration. Nat Commun 13(1):6901
pubmed: 36371497
pmcid: 9653399
doi: 10.1038/s41467-022-34620-y
Deshaies J-E et al (2018) TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis. Brain J Neurol 141(5):1320–1333
doi: 10.1093/brain/awy062
Ishiguro A et al (2020) Molecular dissection of ALS-linked TDP-43 - involvement of the Gly-rich domain in interaction with G-quadruplex mRNA. FEBS Lett 594(14):2254–2265
pubmed: 32337711
doi: 10.1002/1873-3468.13800
Kabashi E et al (2010) Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet 19(4):671–683
pubmed: 19959528
doi: 10.1093/hmg/ddp534
Chiang H-H et al (2012) Novel TARDBP mutations in Nordic ALS patients. J Hum Genet 57(5):316–319
pubmed: 22456481
doi: 10.1038/jhg.2012.24
Naruse H et al (2021) Loss-of-function variants in NEK1 are associated with an increased risk of sporadic ALS in the Japanese population. J Hum Genet 66(3):237–241
pubmed: 32920598
doi: 10.1038/s10038-020-00830-9
Kim G et al (2020) ALS genetics: gains, losses, and implications for future therapies. Neuron 108(5):822–842
pubmed: 32931756
pmcid: 7736125
doi: 10.1016/j.neuron.2020.08.022
Yao L et al (2021) NEK1 mutations and the risk of amyotrophic lateral sclerosis (ALS): a meta-analysis. Neurol Sci 42(4):1277–1285
pubmed: 33462636
doi: 10.1007/s10072-020-05037-6
Riva N et al (2022) Variants in a Cohort of Italian patients with amyotrophic lateral sclerosis. Front Neurosci 16:833051
pubmed: 35495032
pmcid: 9048593
doi: 10.3389/fnins.2022.833051
Bánfai Z et al (2017) Novel phenotypic variant in the MYH7 spectrum due to a stop-loss mutation in the C-terminal region: a case report. BMC Med Genet 18(1):105
pubmed: 28927399
pmcid: 5606036
doi: 10.1186/s12881-017-0463-y
Lu Y, Almeida S, Gao F-B (2021) TBK1 haploinsufficiency in ALS and FTD compromises membrane trafficking. Acta Neuropathol 142(1):217–221
pubmed: 34081168
pmcid: 8500533
doi: 10.1007/s00401-021-02331-1
Libonati L et al (2022) A novel homozygous mutation in TBK1 gene causing ALS-FTD. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 43(3):2101–2104
An H et al (2019) ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol Commun 7(1):7
pubmed: 30642400
pmcid: 6330737
doi: 10.1186/s40478-019-0658-x
Grassano M et al (2022) Phenotype analysis of fused in sarcoma mutations in amyotrophic lateral sclerosis. Neurol Genet 8(5):e200011
pubmed: 36105853
pmcid: 9469212
doi: 10.1212/NXG.0000000000200011
Groen EJ et al (2010) FUS mutations in familial amyotrophic lateral sclerosis in the Netherlands. Arch Neurol 67(2):224–230
pubmed: 20142531
doi: 10.1001/archneurol.2009.329
Abramzon YA et al (2020) The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci 14:42
pubmed: 32116499
pmcid: 7012787
doi: 10.3389/fnins.2020.00042
Kirola L, Mukherjee A, Mutsuddi M (2022) Recent updates on the genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Mol Neurobiol 59(9):5673–5694
pubmed: 35768750
doi: 10.1007/s12035-022-02934-z
Tohnai G et al (2021) Mutation screening of the DNAJC7 gene in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging 113:131–136
pubmed: 35039179
doi: 10.1016/j.neurobiolaging.2021.12.002
Jih K-Y et al (2020) Rapid progressive ALS in a patient with a DNAJC7 loss-of-function mutation. Neurol Genet 6(5):e503
pubmed: 33062890
pmcid: 7524575
doi: 10.1212/NXG.0000000000000503
Miao Y et al (2021) related autosomal recessive lower motor neuron disease with dysmyelination in peripheral nerves. Clin Neuropathol 40(6):328–332
pubmed: 34236308
doi: 10.5414/NP301377
Kim HJ et al (2013) Mutations in the PLEKHG5 gene is relevant with autosomal recessive intermediate Charcot-Marie-Tooth disease. Orphanet J Rare Dis 8:104
pubmed: 23844677
pmcid: 3728151
doi: 10.1186/1750-1172-8-104
Maystadt I et al (2007) The nuclear factor kappaB-activator gene PLEKHG5 is mutated in a form of autosomal recessive lower motor neuron disease with childhood onset. Am J Hum Genet 81(1):67–76
pubmed: 17564964
pmcid: 1950913
doi: 10.1086/518900
Fenoglio C et al (2009) Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer’s disease. J Alzheimer’s Dis: JAD 18(3):603–612
pubmed: 19625741
doi: 10.3233/JAD-2009-1170
Cruchaga C et al (2009) Cortical atrophy and language network reorganization associated with a novel progranulin mutation. Cereb Cortex (New York, NY, 1991) 19(8):1751–1760
doi: 10.1093/cercor/bhn202
Wang J et al (2010) Pathogenic cysteine mutations affect progranulin function and production of mature granulins. J Neurochem 112(5):1305–1315
pubmed: 20028451
doi: 10.1111/j.1471-4159.2009.06546.x
Steele NZ et al (2018) Frequency of frontotemporal dementia gene variants in C9ORF72, MAPT, and GRN in academic versus commercial laboratory cohorts. Adv Genom Genet 8:23–33
doi: 10.2147/AGG.S164047